Literature DB >> 9153719

Factors influencing compliance with antiepileptic drug regimes.

D Buck1, A Jacoby, G A Baker, D W Chadwick.   

Abstract

Failure to comply with drug regimes is prevalent amongst patients with epilepsy and the consequence of this is often an increased risk of further seizures. This paper describes the level of, and influences upon, non-compliance with antiepileptic drug (AED) treatment. A postal questionnaire was sent to an unselected, community-based population of patients with epilepsy. This instrument included questions about patients' AED treatment, any related side-effects, and AED-taking behaviour. Univariate analysis showed that factors associated with compliance were patient age, how important patients felt it was to take drugs as prescribed, whether patients reported feelings of stigma, whether on mono- or polytherapy, whether they were experiencing any side-effects because of AEDs, whether patients had a regular arrangement to see their GP about epilepsy and how easy they found their GP to talk to. Multivariate analysis showed that the strongest predictors of non-compliance were feeling it was not very or not at all important to take AEDs as prescribed, being a teenager, being aged under 60 and being on monotherapy. Further implementation of educational programmes for people with epilepsy would help to improve levels of compliance thereby reducing the risk of unnecessary seizures.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9153719     DOI: 10.1016/s1059-1311(97)80060-x

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  36 in total

1.  Burn injury in epileptic patients: an experience in a tertiary institute.

Authors:  M S Akhtar; I Ahmad; A H Khan; M Fahud Khurram; A Haq
Journal:  Ann Burns Fire Disasters       Date:  2014-09-30

2.  Stigma of people with epilepsy in China: views of health professionals, teachers, employers, and community leaders.

Authors:  Rong-Rong Yang; Wen-Zhi Wang; Dee Snape; Gong Chen; Lei Zhang; Jian-Zhong Wu; Gus A Baker; Xiao-Ying Zheng; Ann Jacoby
Journal:  Epilepsy Behav       Date:  2011-05-24       Impact factor: 2.937

3.  Adherence to medication among outpatient adolescents with epilepsy.

Authors:  Wael M Gabr; Mohamed E E Shams
Journal:  Saudi Pharm J       Date:  2014-05-26       Impact factor: 4.330

4.  Peer support groups as an intervention to decrease epilepsy-associated stigma.

Authors:  Melissa A Elafros; Julius Mulenga; Edward Mbewe; Alan Haworth; Elwyn Chomba; Masharip Atadzhanov; Gretchen L Birbeck
Journal:  Epilepsy Behav       Date:  2013-03-01       Impact factor: 2.937

5.  Long-term tolerability and safety of lamotrigine extended-release: pooled analysis of three clinical trials.

Authors:  Victor Biton; Bassel F Shneker; Dean Naritoku; Anne E Hammer; Alain Vuong; Paul T Caldwell; John A Messenheimer
Journal:  Clin Drug Investig       Date:  2013-05       Impact factor: 2.859

6.  Treatment adherence among adolescents with epilepsy: what really matters?

Authors:  Loretta Carbone; Bradley Zebrack; Melissa Plegue; Sucheta Joshi; Renée Shellhaas
Journal:  Epilepsy Behav       Date:  2013-01-31       Impact factor: 2.937

Review 7.  [Compliance with antiepileptic drugs].

Authors:  U Specht
Journal:  Nervenarzt       Date:  2008-06       Impact factor: 1.214

8.  Difficult to swallow: patient preferences for alternative valproate pharmaceutical formulations.

Authors:  Monali Bhosle; Joshua S Benner; Mitch Dekoven; Jeff Shelton
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

9.  Antiepileptic drug monotherapy: the initial approach in epilepsy management.

Authors:  Erik K St Louis; William E Rosenfeld; Thomas Bramley
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

10.  Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations.

Authors:  Akira Fujii; Norio Yasui-Furukori; Taku Nakagami; Takenori Niioka; Manabu Saito; Yasushi Sato; Sunao Kaneko
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.